A defect in the barrier function of the intestinal mucosa has been proposed as important in both the pathogenesis and systemic manifestations of inflammatory bowel disease. After colonoscopy, polymers of polyethylene glycol (PEG) with molecular weights of 414-810 (mean 600), were instilled in the descending colon of patients with ulcerative colitis (n= 17) and in controls without intestinal inflammation (n=8). The patients with active ulcerative colitis (n=6) had a significantly increased uptake of PEGs in the molecular weight range 458-810, measured as urinary excretion over the first 6 hours after instillation. The median values for their excretion were 2-85-3*80% of PEGs instilled compared with 0-32-0-94% for patients in remission (n=11) (p<005-0.01) and 0 17-0 60% for the controls (p<005-0.01). The differences in absorption of PEG 414 did not reach the preset level of statistical significance. There was a positive correlation between PEG absorption and the endoscopic and histological grading of inflammatory activity in the sigmoid colon (p<0O01-0001). These findings support a correlation between the presence of active inflammation and PEG absorption. There was little evidence to support the presence of a primary defect in the colonic barrier in patients with ulcerative colitis.
A defect in the barrier function of the intestinal mucosa has been proposed as an important factor in the pathogenesis of chronic inflammatory bowel disease. '1'0 Assessment of intestinal permeability in ulcerative colitis after the ingestion of various markers has yielded conflicting results."-'9 An intrinsic colonic permeability defect has been proposed in ulcerative colitis, regardless of disease activity, after studies with 99mtechnetium-diethylene-triamino-pentaacetic acid (99mTc-DTPA) and 51chromium-ethylenediaminetetraacetic acid (51Cr-EDTA).'5 1 ' In the latter study, excretion of ingested 5tCr-EDTA was increased in active and extensive colitis, although not in quiescent and distal disease. 7 The absorption of ingested polyethylene glycols (PEGs) has been found to be normal in patients with active ulcerative colitis. '6 '9 In three other studies using 5 Cr-EDTA, no change in intestinal permeability could be shown in patients with ulcerative colitis when compared with controls.'2-4 Oral permeability tests are more likely to reflect small intestinal permeability,2"2' and oral sugar markers may be degraded by colonic bacteria before they cross the mucosa22 rendering them less suitable for assessing colonic permeability. Besides this, there is little, if any, evidence of small bowel pathology in ulcerative colitis, whch makes the use of oral markers in this context questionable.
Regional studies seem more appropriate if one is to assess colonic permeability.'" Three studies on regional intestinal permeability in patients with ulcerative colitis have been published. In two, a tendency towards lower uptakes was noted in patients with ulcerative colitis compared with controls after the rectal deposition of sodium l3liodide,2324 phenolsulphonphthalein, and sulfisoxazole diethanolamine.24 An increased uptake of 5 Cr-EDTA was shown in active disease, returning towards normal during remission.'4 These data on colonic permeability are limited and have not been correlated to the degree of inflammation present. There are, however, experimental studies suggesting a relationship between active intestinal inflammation and permeability.2526
In the present study, we investigated colonic permeability and its relationship to the presence of inflammation by measuring the absorption of PEG 600 after intracolonic deposition following colonoscopy in patients with ulcerative colitis and in controls.
Methods

ENDOSCOPY
At colonoscopy the macroscopic appearance of the mucosa in the splenic flexure, the sigmoid colon, and the rectum was graded according to a modified Baron Patients with active disease receiving steroids (n=4) did not differ from the active group as a whole: the absorption of PEGs in the range 502-810 in these patients was raised (p<005) when compared with patients in remission and controls. Two patients with active disease had no steroids at the time of investigation. One had the highest absorption over the whole PEG range, recovery in the urine varying from 5 43 to 9-13%. The other patient had values (1-37-1-86%) below the medians for the other five patients with active disease, but still higher than those in remission.
In the active group, the lowest excretion (typically below 1%) was found in one patient who later developed renal insufficiency. He had, however, at the time of investigation a normal serum creatinine value.
Patients with active disease and patients in remission were significantly younger than the control patients, p<0Q05. The age distributions in patients with active disease and patients in remission were similar (p>005). When age was introduced as a concomitant variable, the differences in absorption of PEGs were still significant (p<O0O1).
Discussion
This study showed an increased absorption of PEG 600 in active ulcerative colitis, indicating an increased colonic permeability, whereas absorption in patients in remission was similar to that in controls. There was no size selective absorption in any group as judged from the recovery ratios of PEG 766/458. Although the patients in remission showed a slightly higher absorption of PEGs, this rise was not statistically significant. We found little evidence for the existence of an intrinsic colon permeability defect in ulcerative colitis regardless of disease activity, which has been proposed after studies with oral 99mTc-DTPA and 51Cr-EDTA. '5 7 Our findings agree with a previous study that showed an increased absorption in active ulcerative colitis after the colonic administration of 51Cr-EDTA.'4 An increased absorption of PEGs has also been shown in Crohn's colitis, using the same method as in this study, during both active disease and remission. 9 The patients with active disease and the patients with disease in remission were younger than the controls. The age distributions of patients with active disease and in remission were, however, very similar and analysis of variance did not show any influence of age on PEG absorption. No change in intestinal permeation ratios with age has been shown using oral double sugar absorption tests.3' 32 It is not known whether there is an increase in colonic absorption of PEGs with age in humans such as is seen in rats,33 and whether this could have influenced the results.
An increased absorption of PEGs in active ulcerative colitis could be explained by the presence of inflammation resulting in the loss of mucosal integrity. The importance of active inflammation is underlined by the positive correlation we found between the endoscopic and histological grading of inflammation and PEG absorption. In Crohn's disease intestinal permeability for 51Cr-EDTA has been shown to parallel inflammatory activity measured using labelled leukocytes. 34 There are probably other factors also responsible for the differences in permeability observed between patients with and without active disease. It is possible that an increased mucosal blood flow due to the inflammation per se can contribute to increased absorption.35 Ultrastructural changes in colonic mucosa consistent with increased absorption have been described in ulcerative colitis, in both affected and unaffected areas.36 However, there seem to be no morphological studies on the actual uptake of trace substances and their route through the epithelial barrier. Although the kinetics of intestinal absorption of different PEG sizes is not fully known, absorption of PEG 900 is compatible with simple passive diffusion and only minimal transport occurs through the brush border.37 This implies transport through paracellular tight junctions, and disorganisation of tight junctions has been described in Crohn's disease of the ileal mucosa,38 as has increased uptake of PEG 600 in Crohn's colitis. 9 Furthermore, a change in the physicochemical properties of the mucus in the colon3940 may contribute. The 'leakiness' of the colonic epithelial cells in ulcerative colitis shown in vitro,4' is probably of minor importance since PEGs do not cross lipid cell membranes.37
The inflammatory cell infiltrate and its chemical products may influence intestinal permeability in various ways. It has been suggested that increased permeability is the result of changes in the epithelial cell mediated immune response.42 In cultured human intestinal epithelial cell monolayers, the transepithelial resistance fell and the macromolecular permeability increased parallel to the numbers of polymorphonuclear leukocytes that migrated through intercellular occluding junctions. 43 In animal experiments, increased mucosal permeability could be prevented by depletion of granulocytes with antineutrophil serum,2526 and ileal mucosal permeability increased after exposure to neutrophil derived oxidants. 44 The role of chemotactic N-formylated peptides in the regulation of mucosal permeability has recently come to light. These peptides are produced by bacteria normally found in the human bowel45 and in patients with ulcerative colitis.46 Formyl-methionyl-leucyl-phenylalanine (FMLP) is the major chemotactic peptide produced by Escherichia coli.47 N-formylated peptides bind to specific receptors on polymorphonuclear leukocytes4" thereby activating the cells to release such substances as lysosomal enzymes, oxidative metabolites49 and eicosanoids.5( They produce severe colitis after instillation in the colon.5' 52 They cause an increase in gut permeability when installed in the small bowel,53 an increase that is abolished after granulocyte depletion using antineutrophil serum.2526 Furthermore, FMLP activated neutrophils can evoke histamine release from mast cells,54 and histamine and histamine monochloramine enhance ileal permeability. 55 Mucosal prostaglandin E2 is raised in ulcerative colitis,56 57 and its possible influence on colonic permeability is not known. In a segmental perfusion model, however, prostaglandin E2 has been shown to decrease small bowel absorption of PEG and water.58 All these data point to the importance of leukocytes in the regulation of intestinal permeability. Indeed it has been proposed that any increase in permeability in patients with inflammatory bowel disease results from polymorphonuclear transmigration through the intestinal mucosa. 43 Four of our six patients with active disease were on steroid therapy and they still had a greater absorption of PEGs than the patients in remission and controls. This is in agreement with one study comparing patients with and without cortisone and sulphasalazine therapy where no influence on intestinal permeability was shown. '7 In conclusion, we have shown an increase in absorption of PEG 600 molecules after deposition in the colon of patients with active ulcerative colitis. Moreover, PEG absorption correlated to the degree of inflammation as observed endoscopically and histologically. These findings indicate an increase in colonic permeability that most probably represents a change in mucosal barrier function depending on the presence of inflammation, and is not the result of a primary epithelial defect. 
